Fig. 1. (A) Overall survival compared between patients receiving high-dose melphalan conditioning regimen and patients receiving melphalan plus busulfan regimen (P=0.506). (B) Progression-free survival compared between the 2 groups (P=0.0351). MEL, HDMEL; Others, BUMEL.

Blood Res 2018;53:105~109 https://doi.org/10.5045/br.2018.53.2.105